Dr Guy Makin (BA, BM, BCh, PhD, MRCP, FRCPCH) - publications

2011

• Makin GWJ, Dive C. (2011). Targeting Bcl-2 family proteins in childhood leukaemia. In Saha V, Kearns P (Ed.), New agents for the treatment of childhood acute lymphoblastic leukaemia. (pp. 117-142). Springer. eScholarID:127015
• Klymenko T, Brandenburg M, Morrow C, Dive C, Makin G. (2011). The Novel Bcl-2 Inhibitor ABT-737 Is More Effective in Hypoxia and Is Able to Reverse Hypoxia-Induced Drug Resistance in Neuroblastoma Cells. Molecular Cancer Therapeutics, 10(12), 2373-2383. eScholarID:142568 | DOI:10.1158/1535-7163.MCT-11-0326
• Fallica, B., Makin, G. & Zaman, M (2011). Bioengineering approaches to study multidrug resistance in tumor cells. INTEGRATIVE BIOLOGY, 3(5), 529-539. eScholarID:127021 | DOI:10.1039/c0ib00142b
• Harrison, L., Micha, D., Brandenburg, M., Simpson, K., Morrow, C., Denneny, O., Hodgkinson, C., Yunus, Z., Dempsey, C., Roberts, D., Blackhall, F., Makin, G. & Dive, C (2011). Hypoxic human cancer cells are sensitized to BH-3 mimetic-induced apoptosis via downregulation of the Bcl-2 protein Mcl-1. JOURNAL OF CLINICAL INVESTIGATION, 121(3), 1075-1087. eScholarID:127020 | DOI:10.1172/JCI43505
• Holt, S., Brookes, K., Dive, C. & Makin, G (2011). Down-regulation of XIAP by AEG35156 in paediatric tumour cells induces apoptosis and sensitises cells to cytotoxic agents. Oncol Rep, 25(4), 1177-81. eScholarID:127025 | PMID:21286665 | DOI:10.3892/or.2011.1167

2010

• Amoroso, L., Valteau-Couanet, D., Makin, G., Ladenstein, R., Conte, M., Luksch, R., Battaglia, F., Viscardi, E., Zanazzo, A., Asaftei, S., D'Angelo, P., Di Cataldo, A., Galleni, B., Nantron, M. & Garaventa, A (2010). PRELIMINARY RESULTS OF THE AAOCIATION TOPOTECAN-VINCRISTINE-DOXURUBICIN IN PATIENTS WITH METASTATIC NEUROBLASTOMA POORLY RESPONSIVE TO FIRST-LINE THERAPY (COJEC). eScholarID:127023

2009

• Hussein, D, Holt, S, Brookes, K, Klymenko, T, Adamski, JJ, Hogg, A, Estlin, E, Ward, T, Dive, C, Makin, GWJ. (2009). Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours. Br J Cancer, eScholarID:1d32668 | DOI:10.1038/sj.bjc.6605100

2008

• Adamski J, Steggall M, Yeoh K, Sutton R, Makin GWJ. (2008). Outcome of gram negative infection in immunocompromised children. Pediatr Blood Cancer, 51( 4), eScholarID:1d32669 | DOI:10.1002/pbc.21587
• Adamski J, Estlin E, Makin GWJ. (2008). The cellular adaptations to hypoxia as novel therapeutic targets in childhood cancer. Cancer Treat Rev, 34( 3), eScholarID:1d32672 | DOI:10.1016/j.ctrv.2007.11.005

2006

• Hussein Deema, Estlin Edward, Dive C, Makin GWJ. (2006). Chronic hypoxia promotes HIF-1α-dependent resistance to etoposide and vincristine in neuroblastoma cells. Molecular Cancer Therapeutics, 5, 2241-2248. eScholarID:1d27522 | DOI:10.1158/1535-7163.MCT-06-0145
• Edge BJ, Holmes D, Makin GWJ. (2006). Sperm banking in adolescent cancer patients. Archives of Disease in Childhood, 91, 149-152. eScholarID:1d12575 | DOI:10.1136/adc.2005.075242
• Dean, E., Ranson, M., Blackhall, F., Makin, G., Ward, T., Houghten, R., Pinilla, C., Welsh, K., Reed, J. & Dive, C (2006). Preclinical development of xiapuradamib therapy for lung cancer. eScholarID:127022

2005

• Howell L, Mensah A, Brennan BMD, Makin GWJ. (2005). Detection of recurrence in childhood solid tumours. Cancer, 103, 1274-1279. eScholarID:1d11693 | DOI:10.1002/cncr.20896

2003

• Makin GWJ, Dive C. (2003). Recent advances in understanding apoptosis: new therapeutic opportunities in cancer chemotherapy. Trends Mol Med, 9(6), 251-5. eScholarID:1d7331

2001

• Makin GWJ, Dive C. (2001). Apoptosis and cancer chemotherapy. Trends in Cell Biology, 11, S22-26. eScholarID:1d3877
• Makin GWJ, Bernard m Corfe, Griffiths GG.J, Thistlethwaite AA, Hickman JJ, Dive C. (2001). Damage-induced Bax N-terminal change, translocation to mitochondria and formation of Bax dimers/complexes occur regardless of cell fate. The EMBO Journal, 20, 6306-6315. eScholarID:1d1947 | DOI:10.1093/emboj/20.22.6306

1989

• MAKIN, G., LOHNES, D., BYFORD, V., RAY, R. & JONES, G (1989). TARGET-CELL METABOLISM OF 1,25-DIHYDROXYVITAMIN-D3 TO CALCITROIC ACID - EVIDENCE FOR A PATHWAY IN KIDNEY AND BONE INVOLVING 24-OXIDATION. BIOCHEMICAL JOURNAL, 262(1), 173-180. eScholarID:127024